Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

Survey results published: Patient understanding of biomarker testing in non-small cell lung cancer (NSCLC) We surveyed patients & caregivers to assess awareness, knowledge & attitudes surrounding biomarker testing in NSCLC 📹 The results highlight gaps we can address to better support shared decision-making From medical experts Prof. Christian Rolfo...

lung_connect's profile picture

LUNG CONNECT powered by COR2ED

1,024 subscribers

2,703,909 görüntüleme • 1 ay önce •via X (Twitter)

Bilim & TeknolojiSağlık & İyilikHaberler & Politika
LIVE

Anya Rossi• Live Now

Private livecam show

0 Yorum

Yorum bulunmuyor

Orijinal gönderinin yorumları burada görünecek

Benzer Videolar

Catch up on 𝘏𝘌𝘙2-mutant non-small cell lung cancer (NSCLC) data presented at ASCO 2026 Dr Herbert Loong, MBBS, FASCO & Dr Isabel Preeshagul joined us at ASCO 2026 to share their views on data emerging from the meeting 📺 Watch the video to get their expert insights on data from SOHO-01, Beamion LUNG-3, PRO results from the Beamion LUNG-1 trial, and advances in HER2 testing Programme endorsed by ICAN, International Cancer Advocacy Network, Biomarker Collaborative , Exon 20 Group, a multistakeholder organization & International Society of Liquid Biopsy Supported by an Independent Educational Grant from Bayer
4:40

Catch up on 𝘏𝘌𝘙2-mutant non-small cell lung cancer (NSCLC) data presented at ASCO 2026 Dr Herbert Loong, MBBS, FASCO & Dr Isabel Preeshagul joined us at ASCO 2026 to share their views on data emerging from the meeting 📺 Watch the video to get their expert insights on data from SOHO-01, Beamion LUNG-3, PRO results from the Beamion LUNG-1 trial, and advances in HER2 testing Programme endorsed by ICAN, International Cancer Advocacy Network, Biomarker Collaborative , Exon 20 Group, a multistakeholder organization & International Society of Liquid Biopsy Supported by an Independent Educational Grant from Bayer

LUNG CONNECT powered by COR2ED

841,885 görüntüleme • 17 gün önce

Personalised treatment in childhood cancer: A journey through 𝘕𝘛𝘙𝘒 fusion testing 📺Video for patients & families – please share with your network From Linet Menachery, patient advocate and mother of a child diagnosed with an 𝘕𝘛𝘙𝘒 fusion-positive pediatric cancer Endorsed by NTRKers, ICAN, International Cancer Advocacy Network & Biomarker Collaborative Supported by an Independent Educational Grant from Bayer
4:51

Personalised treatment in childhood cancer: A journey through 𝘕𝘛𝘙𝘒 fusion testing 📺Video for patients & families – please share with your network From Linet Menachery, patient advocate and mother of a child diagnosed with an 𝘕𝘛𝘙𝘒 fusion-positive pediatric cancer Endorsed by NTRKers, ICAN, International Cancer Advocacy Network & Biomarker Collaborative Supported by an Independent Educational Grant from Bayer

COR2ED

5,214,734 görüntüleme • 5 ay önce

Lung cancer e-learning for HCPs Topic: the evolving TROP2-directed ADC landscape in metastatic NSCLC + strategies to optimise the treatment experience Endorsed by ICAN, International Cancer Advocacy Network, Exon 20 Group, a multistakeholder organization & Biomarker Collaborative Supported by an Independent Educational Grant from AstraZeneca 📹
1:15

Lung cancer e-learning for HCPs Topic: the evolving TROP2-directed ADC landscape in metastatic NSCLC + strategies to optimise the treatment experience Endorsed by ICAN, International Cancer Advocacy Network, Exon 20 Group, a multistakeholder organization & Biomarker Collaborative Supported by an Independent Educational Grant from AstraZeneca 📹

LUNG CONNECT powered by COR2ED

4,932,060 görüntüleme • 1 ay önce

ADCs in HER2+ metastatic breast cancer: management of adverse events Get step-by-step strategies to support effective management of T-DXd–related adverse events in HER2+ mBC > N/V > Fatigue > Interstitial lung disease (rare but critical) From Prof. Shaheenah Dawood, Dr Sara Tolaney, Prof. Javier Cortes MD PhD, Carla Whitbread, Dr Grazyna Suchodolska & Prof. Giuseppe Curigliano Endorsed by the European Oncology Nursing Society (@cancernurseEU) and Europa Donna Supported by an Independent Educational Grant from AstraZeneca
3:41

ADCs in HER2+ metastatic breast cancer: management of adverse events Get step-by-step strategies to support effective management of T-DXd–related adverse events in HER2+ mBC > N/V > Fatigue > Interstitial lung disease (rare but critical) From Prof. Shaheenah Dawood, Dr Sara Tolaney, Prof. Javier Cortes MD PhD, Carla Whitbread, Dr Grazyna Suchodolska & Prof. Giuseppe Curigliano Endorsed by the European Oncology Nursing Society (@cancernurseEU) and Europa Donna Supported by an Independent Educational Grant from AstraZeneca

BREAST CANCER CONNECT powered by COR2ED

7,264,152 görüntüleme • 5 ay önce

GI CONNECT podcast episode Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) Dr. Shubham Pant & Prof. Efrat Dotan MD discuss chemotherapy strategies that matter Conversation topics include: - Efficacy & safety profiles - Relevance of mode of delivery - Cause of toxicities - Strategies to manage side effects 📹 Highlights video in this post Endorsed by ICAN, International Cancer Advocacy Network Digestive Cancers Europe The National Pancreas Foundation PanCAN Supported by an Independent Educational Grant from Ipsen USA
4:31

GI CONNECT podcast episode Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) Dr. Shubham Pant & Prof. Efrat Dotan MD discuss chemotherapy strategies that matter Conversation topics include: - Efficacy & safety profiles - Relevance of mode of delivery - Cause of toxicities - Strategies to manage side effects 📹 Highlights video in this post Endorsed by ICAN, International Cancer Advocacy Network Digestive Cancers Europe The National Pancreas Foundation PanCAN Supported by an Independent Educational Grant from Ipsen USA

GI CONNECT powered by COR2ED

1,202,878 görüntüleme • 10 ay önce

THE OncoAlert 🚨 VJ Oncology Journal Club A Great Pleasure to have Misty Dawn Shields 🇺🇸of The Shields Lab Guides us through her paper out on ACS Journal Cancer TOP ADVANCES in #SCLC 🫁 #LungCancer Dr. Misty Shields guides us through this great paper out on Cancer (ACS) on the TOP advances in Small Cell Lung Cancer. Small cell lung cancer (SCLC) remains a leading cause of cancer mortality, with its aggressive nature and frequent relapse leading to poor outcomes. In recent years, immunotherapy has provided some survival benefits, and in 2024, key breakthroughs have significantly improved patient outcomes. Notable advances include the use of consolidative durvalumab immunotherapy for limited-stage SCLC, new insights into timing immunotherapy with radiation, and promising treatments such as the bispecific T-cell engager tarlatamab and antibody-drug conjugates. Precision medicine approaches, like neuroendocrine subtyping, may guide future treatments, while advocacy efforts, such as the Small Cell SMASHERS group SmallCellSMASHERS , offer new support for patients with this historically stigmatized disease. ​Misty Dawn Shields MD PhD (Presenter and first author) Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA Co Authors Lauren Averett Byers, MD Anne Chiang Lung Christian Rolfo gilberto lopes Narjust Florez, MD, FASCO Stephen V Liu, MD H. Jack West, MD, FASCO Bartomeu Massuti Dr. Antonio Calles 🫁🚭 Sébastien Couraud 🫁🚭🌍 Solange Peters Umberto Malapelle Giannis Mountzios Charu Aggarwal, MD, MPH, FASCO Christine Lovly, MD, PhD, FASCO Jill Feldman Ben Solomon Vanita Noronha, MBBS MD DM Sanjay Popat Jordi Remon Jarushka Naidoo Martin Reck Dr. Estela Rodriguez Julien Mazieres TerriConneran #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD Dr. Iván R. González Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD Bárbara Melão, MD, PhD Dr Joseph McCollom DO Erman Akkus Luca Arecco, MD Gaia Griguolo Kristina Jankovic, MD
4:17

THE OncoAlert 🚨 VJ Oncology Journal Club A Great Pleasure to have Misty Dawn Shields 🇺🇸of The Shields Lab Guides us through her paper out on ACS Journal Cancer TOP ADVANCES in #SCLC 🫁 #LungCancer Dr. Misty Shields guides us through this great paper out on Cancer (ACS) on the TOP advances in Small Cell Lung Cancer. Small cell lung cancer (SCLC) remains a leading cause of cancer mortality, with its aggressive nature and frequent relapse leading to poor outcomes. In recent years, immunotherapy has provided some survival benefits, and in 2024, key breakthroughs have significantly improved patient outcomes. Notable advances include the use of consolidative durvalumab immunotherapy for limited-stage SCLC, new insights into timing immunotherapy with radiation, and promising treatments such as the bispecific T-cell engager tarlatamab and antibody-drug conjugates. Precision medicine approaches, like neuroendocrine subtyping, may guide future treatments, while advocacy efforts, such as the Small Cell SMASHERS group SmallCellSMASHERS , offer new support for patients with this historically stigmatized disease. ​Misty Dawn Shields MD PhD (Presenter and first author) Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA Co Authors Lauren Averett Byers, MD Anne Chiang Lung Christian Rolfo gilberto lopes Narjust Florez, MD, FASCO Stephen V Liu, MD H. Jack West, MD, FASCO Bartomeu Massuti Dr. Antonio Calles 🫁🚭 Sébastien Couraud 🫁🚭🌍 Solange Peters Umberto Malapelle Giannis Mountzios Charu Aggarwal, MD, MPH, FASCO Christine Lovly, MD, PhD, FASCO Jill Feldman Ben Solomon Vanita Noronha, MBBS MD DM Sanjay Popat Jordi Remon Jarushka Naidoo Martin Reck Dr. Estela Rodriguez Julien Mazieres TerriConneran #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD Dr. Iván R. González Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD Bárbara Melão, MD, PhD Dr Joseph McCollom DO Erman Akkus Luca Arecco, MD Gaia Griguolo Kristina Jankovic, MD

OncoAlert

14,778 görüntüleme • 1 yıl önce

Megyn Kelly sat down with Dr. Patrick Soon-Shiong to discuss his revolutionary cancer protocol—a treatment that has already extended lives by years for patients with terminal diagnoses, including the late Senator Harry Reid. The Science Behind the Breakthrough Dr. Soon-Shiong’s approach challenges conventional cancer treatments like chemotherapy and radiation, which destroy the immune system’s natural killer (NK) cells and T-cells—critical for fighting cancer. His BioStripe treatment works by rebuilding the immune system, even in patients who have exhausted all other options. Real Patients, Miraculous Results Merkel cell carcinoma (5th-line treatment): Complete remission—patient lived 6+ years and didn’t die from cancer. Bladder cancer: Patients still alive 10-11 years later. Triple-negative breast cancer: Multiple complete remissions. Metastatic pancreatic cancer: One patient disease-free after 5 years, now 6+ years and counting. FDA Roadblocks & Lost Time Despite undeniable success, Dr. Soon-Shiong faced years of resistance from regulators. In 2015, he proposed testing his method before chemo/radiation—but the FDA insisted on starting with end-stage patients. After 700,000 pages of submissions, approval finally came in late 2024. The Future: Beyond Cancer This treatment isn’t just for cancer—it’s showing promise against sepsis and severe infections. One recent case: A Valley Fever patient on a ventilator, given last rites—fully recovered after treatment. The Urgent Question Why is bureaucracy slowing down a therapy that could save millions? With pancreatic cancer, glioblastoma, and lung cancer patients still dying every day, how many more lives could have been saved if this had been fast-tracked?
3:46

Megyn Kelly sat down with Dr. Patrick Soon-Shiong to discuss his revolutionary cancer protocol—a treatment that has already extended lives by years for patients with terminal diagnoses, including the late Senator Harry Reid. The Science Behind the Breakthrough Dr. Soon-Shiong’s approach challenges conventional cancer treatments like chemotherapy and radiation, which destroy the immune system’s natural killer (NK) cells and T-cells—critical for fighting cancer. His BioStripe treatment works by rebuilding the immune system, even in patients who have exhausted all other options. Real Patients, Miraculous Results Merkel cell carcinoma (5th-line treatment): Complete remission—patient lived 6+ years and didn’t die from cancer. Bladder cancer: Patients still alive 10-11 years later. Triple-negative breast cancer: Multiple complete remissions. Metastatic pancreatic cancer: One patient disease-free after 5 years, now 6+ years and counting. FDA Roadblocks & Lost Time Despite undeniable success, Dr. Soon-Shiong faced years of resistance from regulators. In 2015, he proposed testing his method before chemo/radiation—but the FDA insisted on starting with end-stage patients. After 700,000 pages of submissions, approval finally came in late 2024. The Future: Beyond Cancer This treatment isn’t just for cancer—it’s showing promise against sepsis and severe infections. One recent case: A Valley Fever patient on a ventilator, given last rites—fully recovered after treatment. The Urgent Question Why is bureaucracy slowing down a therapy that could save millions? With pancreatic cancer, glioblastoma, and lung cancer patients still dying every day, how many more lives could have been saved if this had been fast-tracked?

Camus

615,291 görüntüleme • 1 yıl önce

A New Dawn in the Cancer War: Pioneering "BioShield" Technology Achieves Long-Term Remission Where Others Failed A stunning revelation from Dr. Patrick Soon-Shiong on the dawn of a new medical era. He details a breakthrough he calls "BioShield," a technology designed to prevent cancer by fundamentally educating the body's own immune system. Forget conventional vaccines. This isn't about antibodies. This is about creating a living, intelligent defense system within you. Here’s the concept: "BioShield" educates your T-cells to become elite "memory" cells. They then hide in your bone marrow, lying in wait. When a cancerous cell appears, they emerge to seek and destroy it—stopping cancer before it can ever gain a foothold. This isn't science fiction. It's peer-reviewed, published science with the National Cancer Institute (NCI). And the results are nothing short of remarkable: ➡️ Bladder Cancer: Patients who failed all other treatments and faced radical bladder removal have achieved complete remission for nine years after a simple injection. No surgery. Just a functional cure. ➡️ Pancreatic Cancer: A disease with a grim prognosis, now seeing patients disease-free for five years. The late Senator Harry Reid, after being told by others not to pursue it, saw his tumor markers normalize and lived two active, cancer-free years. ➡️ Merkel Cell Carcinoma & Head/Neck Cancer: Stories of complete responses in patients given weeks to live, with one living nine years and another saved from hospice when his ulcerating tumor melted away. Dr. Soon-Shiong is reframing the conversation. This isn't a "vaccine" in the traditional sense. It's Project BioShield—a proactive, cellular guardian for the body. The takeaway? We are transitioning from toxic, reactive cancer therapies to intelligent, preemptive protection. The age of the immune system as our most powerful shield against cancer has arrived. What are your thoughts on this "BioShield" approach to cancer?
5:12

A New Dawn in the Cancer War: Pioneering "BioShield" Technology Achieves Long-Term Remission Where Others Failed A stunning revelation from Dr. Patrick Soon-Shiong on the dawn of a new medical era. He details a breakthrough he calls "BioShield," a technology designed to prevent cancer by fundamentally educating the body's own immune system. Forget conventional vaccines. This isn't about antibodies. This is about creating a living, intelligent defense system within you. Here’s the concept: "BioShield" educates your T-cells to become elite "memory" cells. They then hide in your bone marrow, lying in wait. When a cancerous cell appears, they emerge to seek and destroy it—stopping cancer before it can ever gain a foothold. This isn't science fiction. It's peer-reviewed, published science with the National Cancer Institute (NCI). And the results are nothing short of remarkable: ➡️ Bladder Cancer: Patients who failed all other treatments and faced radical bladder removal have achieved complete remission for nine years after a simple injection. No surgery. Just a functional cure. ➡️ Pancreatic Cancer: A disease with a grim prognosis, now seeing patients disease-free for five years. The late Senator Harry Reid, after being told by others not to pursue it, saw his tumor markers normalize and lived two active, cancer-free years. ➡️ Merkel Cell Carcinoma & Head/Neck Cancer: Stories of complete responses in patients given weeks to live, with one living nine years and another saved from hospice when his ulcerating tumor melted away. Dr. Soon-Shiong is reframing the conversation. This isn't a "vaccine" in the traditional sense. It's Project BioShield—a proactive, cellular guardian for the body. The takeaway? We are transitioning from toxic, reactive cancer therapies to intelligent, preemptive protection. The age of the immune system as our most powerful shield against cancer has arrived. What are your thoughts on this "BioShield" approach to cancer?

Camus

31,209 görüntüleme • 8 ay önce

The Pillars of Cancer Treatment Are a Lie. Chemo and Radiation Aren't Just Brutal—They're Actively Destroying Your Natural Killer Cells, the Very Thing Standing Between You and Cancer. A stunning revelation from Dr. Patrick Soon-Shiong that reframes our entire battle against cancer. He shares a truth 460 million years in the making. Within every one of us is an ancient gift, a cell bestowed by the very process of creation: the Natural Killer (NK) cell. Dr. Soon-Shiong explains that this cell is our fundamental biological shield, the key reason humanity has survived infection, trauma, and cancer across millennia. Yet, for decades, modern medicine has waged a devastating war on this very protector. How? With the very pillars of our oncological arsenal: high-dose chemotherapy, radiation, steroid therapy, and even newer modalities. These treatments, while aimed at cancer, systematically destroy the NK cells designed to defend us. A single dose of radiation can obliterate this natural defense for a year, leaving patients vulnerable. Dr. Soon-Shiong presents a paradigm-shattering question: What if, instead of attacking the body’s innate protection, we learned to unlock and unleash it? The answer is here. After a lifetime of research, a method has been discovered and approved to activate the body as its own factory. A single intervention—a “bio-shield”—that proliferates these natural killer cells, empowering them to do what they were designed to do: protect you from cancer. The results? Real patients with bladder cancer, free of disease for a decade. This is not a future promise. This is a present reality, approved in 2024. Dr. Soon-Shiong credits the current administration for its role in moving this breakthrough forward for the entire nation. The era of destroying the body to save it is ending. The era of activating our 460-million-year-old innate defense has begun.
2:58

The Pillars of Cancer Treatment Are a Lie. Chemo and Radiation Aren't Just Brutal—They're Actively Destroying Your Natural Killer Cells, the Very Thing Standing Between You and Cancer. A stunning revelation from Dr. Patrick Soon-Shiong that reframes our entire battle against cancer. He shares a truth 460 million years in the making. Within every one of us is an ancient gift, a cell bestowed by the very process of creation: the Natural Killer (NK) cell. Dr. Soon-Shiong explains that this cell is our fundamental biological shield, the key reason humanity has survived infection, trauma, and cancer across millennia. Yet, for decades, modern medicine has waged a devastating war on this very protector. How? With the very pillars of our oncological arsenal: high-dose chemotherapy, radiation, steroid therapy, and even newer modalities. These treatments, while aimed at cancer, systematically destroy the NK cells designed to defend us. A single dose of radiation can obliterate this natural defense for a year, leaving patients vulnerable. Dr. Soon-Shiong presents a paradigm-shattering question: What if, instead of attacking the body’s innate protection, we learned to unlock and unleash it? The answer is here. After a lifetime of research, a method has been discovered and approved to activate the body as its own factory. A single intervention—a “bio-shield”—that proliferates these natural killer cells, empowering them to do what they were designed to do: protect you from cancer. The results? Real patients with bladder cancer, free of disease for a decade. This is not a future promise. This is a present reality, approved in 2024. Dr. Soon-Shiong credits the current administration for its role in moving this breakthrough forward for the entire nation. The era of destroying the body to save it is ending. The era of activating our 460-million-year-old innate defense has begun.

Camus

150,992 görüntüleme • 10 ay önce

"Biopsies Spread Cancer...Biopsies Are The Kiss Of Death. The Needle Punches A Hole In The Tumor, Dragging Cancer Cells & Spreading Them." Dr Ben Johnson Doctors Finally Admit That The Very Test Being Pushed On Patients Is Causing Cancer To Metastasize All Throughout The Body. The body self-contains a tumor within a fibrin sheath. A needle biopsy breaks the seal of the tumor that kept it contained & allows the pathogenic toxins &/or parasites to be unleashed. When a hornet's nest is poked, it doesn't calm the hive...it angers & scatters. That’s what happens when a needle pierces a tumor. Cancer cells are dragged into new territory, inflammation flares, the immune system gets distracted, and the “nest” gets angrier. Cells are dragged along the needle tract. Local inflammation activates tumor growth. The immune system is suppressed & cancer cells invade tissue, blood & lymph. Biopsies trigger metastasis, inflammation & tumor seeding: "Biopsy of primary tumors resulted in significantly increased incidence & number of lung metastasis."(PMID 25061543) "Biopsies promote intraperitoneal tumor dissemination & progression." (PMID 23258276) "Core needle biopsy of breast tumors increases distant metastases. (PMID 25425969) "Biopsies lead to tumor cell dissemination & seeding of malignant tumors." (PMID 22686607) "Human breast cancer biopsies enhance adjacent cancer cell proliferation." (PMID 27249999) Top Doctors Are Now Admitting 'That Standard Of Care' Is Killing Patients: "Manipulation of an intact tumor...is associated with an increase in the incidence of sentinel node metastasis." (John Wayne Cancer Institute 2022) "Cutting out a section...endangered the person's life by aggravating the malignant growth." (Dr Perry Nichols) "Biopsies spread early cancers." (Dr Jonathan Wright) "Biopsies introduce cancer cells into the bloodstream." (Dr Leonard Gomella) "Biopsies cause cancer cells to spread & the risk is higher in certain types of cancers like prostate & kidney cancers." (Dr Hal Schofield) "Biopsies cause cancer to disseminate further into the body & this has serious implications to patient outcomes." (Dr Robert Nagourney) Alternative Tests That Do Not Disturb Fibrin Sheath Of The Encapsulated Tumor: 1⃣ Multiparametric MRI (pmMRI): Non-invasive. No ionizing radiation. Detects structure & function in high resolution. 2⃣ Color Doppler Ultrasound: Maps tumor blood flow in real time. No radiation. No compression damage. 3⃣ Liquid Biopsy (ctDNA /CTC Testing): Blood test for cancer DNA or cells. No mechanical disruption of tumors. 4⃣ Thermography: Non-radiation, non-invasive technique that uses infrared cameras to detect heat patterns in tumors. Information is anti-fear. Knowledge is power. It gives you choices. It gives you power. If you’ve been diagnosed, please don’t rush. Research. Ask questions. Trust your intuition. Sometimes slowing down is the most urgent thing you can do. The cancer industrial complex is a powerful profit model & needs a massive overhaul. Too many patients blindly walk into these procedures without informed consent, never being told the risks. You can choose to not disturb the tumor at all & instead implement a protocol to shrink & enable the body to eradicate the tumor all together. Many cases of cancer tumors are actually parasitic eggs sacs misdiagnosed as cancer. There are ways to diagnose cancer without the risk of spread & acceleration. And ways to prevent & treat cancer without the harm of Chemotherapy & Radiation. There is a groundbreaking protocol by Dr William Makis, Dr Paul Marik & others that uses Ivermectin, Fenbendazole, Methylene Blue, Fasting, Ketogenic Diet & other proven cancer remission strategies that addresses cancer & parasites simultaneously. ⏩ ⏪ 👇Seeding Tumor Cells Into Metastasis👇 👇Needle Biopsy Promotes Metastasis👇 👇Needle Biopsy Accelerates Cancer👇 Speaker: Justin Stellman
1:32

"Biopsies Spread Cancer...Biopsies Are The Kiss Of Death. The Needle Punches A Hole In The Tumor, Dragging Cancer Cells & Spreading Them." Dr Ben Johnson Doctors Finally Admit That The Very Test Being Pushed On Patients Is Causing Cancer To Metastasize All Throughout The Body. The body self-contains a tumor within a fibrin sheath. A needle biopsy breaks the seal of the tumor that kept it contained & allows the pathogenic toxins &/or parasites to be unleashed. When a hornet's nest is poked, it doesn't calm the hive...it angers & scatters. That’s what happens when a needle pierces a tumor. Cancer cells are dragged into new territory, inflammation flares, the immune system gets distracted, and the “nest” gets angrier. Cells are dragged along the needle tract. Local inflammation activates tumor growth. The immune system is suppressed & cancer cells invade tissue, blood & lymph. Biopsies trigger metastasis, inflammation & tumor seeding: "Biopsy of primary tumors resulted in significantly increased incidence & number of lung metastasis."(PMID 25061543) "Biopsies promote intraperitoneal tumor dissemination & progression." (PMID 23258276) "Core needle biopsy of breast tumors increases distant metastases. (PMID 25425969) "Biopsies lead to tumor cell dissemination & seeding of malignant tumors." (PMID 22686607) "Human breast cancer biopsies enhance adjacent cancer cell proliferation." (PMID 27249999) Top Doctors Are Now Admitting 'That Standard Of Care' Is Killing Patients: "Manipulation of an intact tumor...is associated with an increase in the incidence of sentinel node metastasis." (John Wayne Cancer Institute 2022) "Cutting out a section...endangered the person's life by aggravating the malignant growth." (Dr Perry Nichols) "Biopsies spread early cancers." (Dr Jonathan Wright) "Biopsies introduce cancer cells into the bloodstream." (Dr Leonard Gomella) "Biopsies cause cancer cells to spread & the risk is higher in certain types of cancers like prostate & kidney cancers." (Dr Hal Schofield) "Biopsies cause cancer to disseminate further into the body & this has serious implications to patient outcomes." (Dr Robert Nagourney) Alternative Tests That Do Not Disturb Fibrin Sheath Of The Encapsulated Tumor: 1⃣ Multiparametric MRI (pmMRI): Non-invasive. No ionizing radiation. Detects structure & function in high resolution. 2⃣ Color Doppler Ultrasound: Maps tumor blood flow in real time. No radiation. No compression damage. 3⃣ Liquid Biopsy (ctDNA /CTC Testing): Blood test for cancer DNA or cells. No mechanical disruption of tumors. 4⃣ Thermography: Non-radiation, non-invasive technique that uses infrared cameras to detect heat patterns in tumors. Information is anti-fear. Knowledge is power. It gives you choices. It gives you power. If you’ve been diagnosed, please don’t rush. Research. Ask questions. Trust your intuition. Sometimes slowing down is the most urgent thing you can do. The cancer industrial complex is a powerful profit model & needs a massive overhaul. Too many patients blindly walk into these procedures without informed consent, never being told the risks. You can choose to not disturb the tumor at all & instead implement a protocol to shrink & enable the body to eradicate the tumor all together. Many cases of cancer tumors are actually parasitic eggs sacs misdiagnosed as cancer. There are ways to diagnose cancer without the risk of spread & acceleration. And ways to prevent & treat cancer without the harm of Chemotherapy & Radiation. There is a groundbreaking protocol by Dr William Makis, Dr Paul Marik & others that uses Ivermectin, Fenbendazole, Methylene Blue, Fasting, Ketogenic Diet & other proven cancer remission strategies that addresses cancer & parasites simultaneously. ⏩ ⏪ 👇Seeding Tumor Cells Into Metastasis👇 👇Needle Biopsy Promotes Metastasis👇 👇Needle Biopsy Accelerates Cancer👇 Speaker: Justin Stellman

Valerie Anne Smith

770,354 görüntüleme • 10 ay önce

🚨Dr. William Makis: Ivermectin Dosing for Cancer Explained In one of his recent talks, Dr. William Makis shared what he considers the most important dosing guide for using Ivermectin in cancer. According to Dr. Makis, the starting dose for most cancers is 1 mg per kilogram of body weight per day For example, a person weighing 60 kg would take 60 mg daily, that’s five 12 mg pills or roughly one teaspoon (6 ml) of liquid ivermectin. He mentioned that Ivermectin has shown positive effects in many types of cancer, including: - Breast cancer - Colon cancer - Lung cancer - Pancreatic cancer - Gastric cancer - Renal cell carcinoma - Leukemias He noted that there is very little research on lymphomas, but that doesn’t mean it won’t work, it simply hasn’t been studied much yet. Important points from Dr. Makis: 1) The anti-cancer effect of Ivermectin appears to be dose dependent. 2) Higher doses may offer better results in more aggressive cancers. 3) For very aggressive cancers (such as pancreatic, leukemia, or brain cancers), he suggests considering 2 mg/kg or even up to 2.5 mg/kg per day. Some patients have used these higher doses for many months with only temporary side effects (such as mild visual disturbances that usually resolve within a few days). Real-world examples include a prostate cancer patient whose PSA dropped from 89 to 11 on 45 mg daily, and a terminal gallbladder cancer case that resolved after 14 months on 2 mg/kg. Dr. Makis emphasizes that Ivermectin is a very safe drug with no reported long-term side effects at 1 mg/kg. He recommends starting at this dose and adjusting upwards depending on the individual case and cancer type. He also stresses that people can safely stay on Ivermectin for months as long as there is active disease. If you're researching Ivermectin for cancer protocols, many people are choosing GENIX MEDS for clean, pharmaceutical-grade Ivermectin with straightforward worldwide delivery. #Ivermectindosage #MakisMD #Genixmeds
5:47

🚨Dr. William Makis: Ivermectin Dosing for Cancer Explained In one of his recent talks, Dr. William Makis shared what he considers the most important dosing guide for using Ivermectin in cancer. According to Dr. Makis, the starting dose for most cancers is 1 mg per kilogram of body weight per day For example, a person weighing 60 kg would take 60 mg daily, that’s five 12 mg pills or roughly one teaspoon (6 ml) of liquid ivermectin. He mentioned that Ivermectin has shown positive effects in many types of cancer, including: - Breast cancer - Colon cancer - Lung cancer - Pancreatic cancer - Gastric cancer - Renal cell carcinoma - Leukemias He noted that there is very little research on lymphomas, but that doesn’t mean it won’t work, it simply hasn’t been studied much yet. Important points from Dr. Makis: 1) The anti-cancer effect of Ivermectin appears to be dose dependent. 2) Higher doses may offer better results in more aggressive cancers. 3) For very aggressive cancers (such as pancreatic, leukemia, or brain cancers), he suggests considering 2 mg/kg or even up to 2.5 mg/kg per day. Some patients have used these higher doses for many months with only temporary side effects (such as mild visual disturbances that usually resolve within a few days). Real-world examples include a prostate cancer patient whose PSA dropped from 89 to 11 on 45 mg daily, and a terminal gallbladder cancer case that resolved after 14 months on 2 mg/kg. Dr. Makis emphasizes that Ivermectin is a very safe drug with no reported long-term side effects at 1 mg/kg. He recommends starting at this dose and adjusting upwards depending on the individual case and cancer type. He also stresses that people can safely stay on Ivermectin for months as long as there is active disease. If you're researching Ivermectin for cancer protocols, many people are choosing GENIX MEDS for clean, pharmaceutical-grade Ivermectin with straightforward worldwide delivery. #Ivermectindosage #MakisMD #Genixmeds

GENIX MEDS

19,941 görüntüleme • 1 ay önce

A Cancer Breakthrough That Changes Everything In a stunning medical advance, Dr. Patrick Soon-Shiong reveals a platform technology achieving near-complete responses in patients with terminal cancers—including brain, pancreatic, and head & neck tumors—after all other treatments failed. This isn't a traditional chemo or radiation. It's a dual approach that empowers the body's own immune system. Here’s the revolutionary breakdown: 1. The "BioShield" Injection: The key is a stabilized form of IL-15 (Interleukin-15), a protein that acts as "food" for your Natural Killer (NK) cells. The NIH tried for a decade to develop IL-15 but failed because it naturally lasts only 2 minutes in the body. Dr. Soon-Shiong's team engineered it to last for 7 days with a simple 5-minute subcutaneous injection, continuously proliferating the patient's NK cells. 2. The Combined Infusion: Patients receive this "BioShield" injection along with an infusion of powerful NK cells, creating a targeted army to attack the cancer. The Proven Results: - Metastatic Pancreatic Cancer: Patients alive 6 years later. - Merkel Cell Carcinoma: Patients surviving 9 years. - Bladder Cancer: Approved by the FDA in April 2024, with patients disease-free for 10 years. - Lung Cancer: In new trials, the therapy has tripled survival for patients who failed everything, including chemo and checkpoint inhibitors. The therapy is also being used preemptively. The NCI has designated it for a trial on patients with Lynch syndrome (1 in 280 Americans), who have an 80% higher risk of cancers, to provide a "Cancer BioShield." The data is based on experience with over 8,000 patients. The challenge now is regulatory. Despite its pan-tumor potential, the current system requires a separate 10-year, 700,000-page approval process for each cancer type. This is a paradigm shift. We don't ask what kind of anemia you have before a blood transfusion. The body needs NK cells and T-cells to fight cancer, regardless of the tumor type.
5:24

A Cancer Breakthrough That Changes Everything In a stunning medical advance, Dr. Patrick Soon-Shiong reveals a platform technology achieving near-complete responses in patients with terminal cancers—including brain, pancreatic, and head & neck tumors—after all other treatments failed. This isn't a traditional chemo or radiation. It's a dual approach that empowers the body's own immune system. Here’s the revolutionary breakdown: 1. The "BioShield" Injection: The key is a stabilized form of IL-15 (Interleukin-15), a protein that acts as "food" for your Natural Killer (NK) cells. The NIH tried for a decade to develop IL-15 but failed because it naturally lasts only 2 minutes in the body. Dr. Soon-Shiong's team engineered it to last for 7 days with a simple 5-minute subcutaneous injection, continuously proliferating the patient's NK cells. 2. The Combined Infusion: Patients receive this "BioShield" injection along with an infusion of powerful NK cells, creating a targeted army to attack the cancer. The Proven Results: - Metastatic Pancreatic Cancer: Patients alive 6 years later. - Merkel Cell Carcinoma: Patients surviving 9 years. - Bladder Cancer: Approved by the FDA in April 2024, with patients disease-free for 10 years. - Lung Cancer: In new trials, the therapy has tripled survival for patients who failed everything, including chemo and checkpoint inhibitors. The therapy is also being used preemptively. The NCI has designated it for a trial on patients with Lynch syndrome (1 in 280 Americans), who have an 80% higher risk of cancers, to provide a "Cancer BioShield." The data is based on experience with over 8,000 patients. The challenge now is regulatory. Despite its pan-tumor potential, the current system requires a separate 10-year, 700,000-page approval process for each cancer type. This is a paradigm shift. We don't ask what kind of anemia you have before a blood transfusion. The body needs NK cells and T-cells to fight cancer, regardless of the tumor type.

Camus

421,950 görüntüleme • 10 ay önce

Today we’re reporting interim Phase 1 clinical data for our REC-617 monotherapy trial – with plans to expand into combination studies in advanced solid tumors. At the AACR Special Conference in Cancer Research, CSO David Hallett shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. 🔹The interim Phase 1 clinical data for REC-617 included: ▫️Dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement; ▫️Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; ▫️In 4 additional patients, a best response of stable disease (SD) for up to 6 months of treatment. Dr. Hallett noted: “Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." 👉Learn more: 🔹Join the Update Call: Tomorrow, Tues., Dec. 10 at 8:30am ET, Dr. Hallett and Dr. Khan will hold a live Update Call webcast to present the preliminary data. ▫️Submit questions for the Update Call here: ▫️Tune in to the Update Call here on X or on: LinkedIn: YouTube:
0:20

Today we’re reporting interim Phase 1 clinical data for our REC-617 monotherapy trial – with plans to expand into combination studies in advanced solid tumors. At the AACR Special Conference in Cancer Research, CSO David Hallett shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. 🔹The interim Phase 1 clinical data for REC-617 included: ▫️Dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement; ▫️Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; ▫️In 4 additional patients, a best response of stable disease (SD) for up to 6 months of treatment. Dr. Hallett noted: “Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." 👉Learn more: 🔹Join the Update Call: Tomorrow, Tues., Dec. 10 at 8:30am ET, Dr. Hallett and Dr. Khan will hold a live Update Call webcast to present the preliminary data. ▫️Submit questions for the Update Call here: ▫️Tune in to the Update Call here on X or on: LinkedIn: YouTube:

Recursion

11,887 görüntüleme • 1 yıl önce

A Physicians Survey Revealed 88.3% Of Doctors Would Refuse Chemotherapy For Their Own Cancer Treatment. The 5 Year Chemo Survival Rate Is Only 2.1%, Yet Most Oncologists Only Offer 'Standard Of Care' To Patients. Dr Seyfried Would Choose The Protocol With Ivermectin & Fasting. American Society of Clinical Oncology (ASCO) Board of Directors has data that oncologists THEMSELVES would not take chemotherapy for cancer even though they advise chemo & radiation as the only 'approved' treatment to their patients. MacKillop & colleagues found that a survey of Canadian doctors who treat lung cancer, only 16% would want chemotherapy for their own treatment if they had a cancer diagnosis. Lind & colleagues interviewed teaching oncologists in Boston & found that only 27% would take chemo for lung cancer. "The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies" cites...The overall contribution of curative & adjuvant cytotoxic chemotherapy to 5-year survival in adults is only 2.3% in Australia & 2.1% in the USA. Cancer treatment is a multi-billion dollar industry. Most oncologists believe that cancer is genetic, but cancer is a metabolic disease. Doctors don’t study nutrition or metabolic therapy & don't even know that chemotherapy historically was a 'weapon of war' mustard gas. Banned from use in war because it is cytotoxic & too inhumane, even against war enemies. The system profits more from lifelong chemo & radiation than natural intervention. Chemotherapy is not the answer to heal the body of cancer. GKI Glucose Ketone Index & Cancer Eradication Based On Otto Warburg's Groundbreaking Research: Cancer cells are metabolically inflexible & cannot use ketone bodies for energy when glucose is limited, unlike healthy cells. A low GKI is achieved by restricting carbohydrates, which lowers blood glucose & increases ketone production. This starves cancer cells of glucose while providing normal cells with an alternative energy source. Research shows a low glucose environment promotes our Natural Killer (NK) cells & T-cells to become even stronger which are crucial for killing cancer. Chemotherapy & radiation actually kills our NK Natural Killer Cells allowing cancer to return even stronger than before conventional treatment. 15 expert physicians & oncologists have published...'Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol.' This is the step by step protocol of fasting, high fat ketogenic diet (eliminating glucose) & using ivermectin, fenbendazole & supportive nutrients with lifestyle changes for cancer treatment remission. This protocol, along with cited research is linked in the replies. Have you used non traditional methods to reverse cancer? Is your cancer in remission thanks to fasting, ivermectin or other alternative protocols? Share and repost this message to increase awareness. It is essential for the public to be informed. Follow my page for further motivational and educational content.
0:59

A Physicians Survey Revealed 88.3% Of Doctors Would Refuse Chemotherapy For Their Own Cancer Treatment. The 5 Year Chemo Survival Rate Is Only 2.1%, Yet Most Oncologists Only Offer 'Standard Of Care' To Patients. Dr Seyfried Would Choose The Protocol With Ivermectin & Fasting. American Society of Clinical Oncology (ASCO) Board of Directors has data that oncologists THEMSELVES would not take chemotherapy for cancer even though they advise chemo & radiation as the only 'approved' treatment to their patients. MacKillop & colleagues found that a survey of Canadian doctors who treat lung cancer, only 16% would want chemotherapy for their own treatment if they had a cancer diagnosis. Lind & colleagues interviewed teaching oncologists in Boston & found that only 27% would take chemo for lung cancer. "The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies" cites...The overall contribution of curative & adjuvant cytotoxic chemotherapy to 5-year survival in adults is only 2.3% in Australia & 2.1% in the USA. Cancer treatment is a multi-billion dollar industry. Most oncologists believe that cancer is genetic, but cancer is a metabolic disease. Doctors don’t study nutrition or metabolic therapy & don't even know that chemotherapy historically was a 'weapon of war' mustard gas. Banned from use in war because it is cytotoxic & too inhumane, even against war enemies. The system profits more from lifelong chemo & radiation than natural intervention. Chemotherapy is not the answer to heal the body of cancer. GKI Glucose Ketone Index & Cancer Eradication Based On Otto Warburg's Groundbreaking Research: Cancer cells are metabolically inflexible & cannot use ketone bodies for energy when glucose is limited, unlike healthy cells. A low GKI is achieved by restricting carbohydrates, which lowers blood glucose & increases ketone production. This starves cancer cells of glucose while providing normal cells with an alternative energy source. Research shows a low glucose environment promotes our Natural Killer (NK) cells & T-cells to become even stronger which are crucial for killing cancer. Chemotherapy & radiation actually kills our NK Natural Killer Cells allowing cancer to return even stronger than before conventional treatment. 15 expert physicians & oncologists have published...'Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol.' This is the step by step protocol of fasting, high fat ketogenic diet (eliminating glucose) & using ivermectin, fenbendazole & supportive nutrients with lifestyle changes for cancer treatment remission. This protocol, along with cited research is linked in the replies. Have you used non traditional methods to reverse cancer? Is your cancer in remission thanks to fasting, ivermectin or other alternative protocols? Share and repost this message to increase awareness. It is essential for the public to be informed. Follow my page for further motivational and educational content.

Joe Tippens

47,858 görüntüleme • 5 ay önce

A revolutionary approach to defeating cancer: Dr. Patrick Soon-Shiong unveils a game-changing strategy In a riveting discussion, Dr. Patrick Soon-Shiong, a pioneering surgeon and biotech innovator, laid out a bold, chess-like strategy to outsmart cancer—an enemy he describes as diabolically clever, hiding from the body’s immune defenses with sinister precision. Forget checkers; this is a war requiring the sophistication of Go, where every move counts. Here’s how Dr. Soon-Shiong’s cutting-edge approach is rewriting the rules of cancer treatment: Step 1: Smoke Out the Enemy Cancer isn’t just a clump of cells—it’s a cunning adversary with genomic tricks that let it cloak itself from killer T-cells. Dr. Soon-Shiong’s protocol starts by exposing the cancer’s hidden receptors. Instead of blasting the tumor with high-dose chemotherapy, he uses a low metronomic dose—a tiny amount that stresses the cancer, forcing it to reveal itself. “It’s like smoking it out,” he explains. The cancer, sensing danger, exposes its surface molecules, making it a target for the immune system. Step 2: Unleash the Body’s Elite Forces With the tumor exposed, Dr. Soon-Shiong deploys the body’s natural killer (NK) cells and T-cells, supercharged by a breakthrough molecule called BioShield. This activates NK cells, stimulates killer T-cells, and—crucially—creates memory T-cells that remember the cancer’s signature. “For the first time, we’re seeing bladder cancer patients in complete remission for nine years, still alive, without losing their bladders,” he revealed. This isn’t just treatment; it’s a long-term defense system. Step 3: Orchestrate a Multi-Front Assault Cancer thrives by suppressing the immune system, but Dr. Soon-Shiong’s approach is a battlefield symphony. He educates T-cells with a tailored vaccine, activates killer macrophages, and suppresses the suppressors—all simultaneously. Radiation? Only in tiny, precise doses (SBRT) to expose, not destroy. “High-dose radiation kills your NK and T-cells,” he warns. This is precision warfare, not carpet bombing. A Future Without Suffering Unlike traditional cancer treatments that leave patients nauseous, bald, and broken, Dr. Soon-Shiong’s protocol is outpatient-based, minimizing suffering. “We’ve treated hundreds of patients this way,” he shared. Even more revolutionary? He envisions treating patients before surgery, using the tumor itself as a vaccine to train the immune system. Imagine a world where cancer is stopped in its tracks without invasive procedures. The American Red Cross of Cancer Dr. Soon-Shiong’s vision goes beyond individual patients. By extracting and cryopreserving NK and T-cells from a single pint of blood, his team can grow billions of these immune warriors, ready to be deployed for anyone. “We could become the American Red Cross of cancer,” he declared, hinting at a future where these innovations could even shape global health policy. Why This Matters Cancer isn’t just a disease; it’s a biological mastermind that demands respect and strategy. Dr. Soon-Shiong’s approach—expose, activate, educate, and suppress—offers hope to millions facing a life-threatening diagnosis. His work proves that with the right tools, we can turn the body into its own greatest weapon. The Call to Action The FDA must recognize this multi-pronged war requires battlefield awareness, not outdated single-drug approvals. Patients deserve access to these life-saving protocols now.
6:39

A revolutionary approach to defeating cancer: Dr. Patrick Soon-Shiong unveils a game-changing strategy In a riveting discussion, Dr. Patrick Soon-Shiong, a pioneering surgeon and biotech innovator, laid out a bold, chess-like strategy to outsmart cancer—an enemy he describes as diabolically clever, hiding from the body’s immune defenses with sinister precision. Forget checkers; this is a war requiring the sophistication of Go, where every move counts. Here’s how Dr. Soon-Shiong’s cutting-edge approach is rewriting the rules of cancer treatment: Step 1: Smoke Out the Enemy Cancer isn’t just a clump of cells—it’s a cunning adversary with genomic tricks that let it cloak itself from killer T-cells. Dr. Soon-Shiong’s protocol starts by exposing the cancer’s hidden receptors. Instead of blasting the tumor with high-dose chemotherapy, he uses a low metronomic dose—a tiny amount that stresses the cancer, forcing it to reveal itself. “It’s like smoking it out,” he explains. The cancer, sensing danger, exposes its surface molecules, making it a target for the immune system. Step 2: Unleash the Body’s Elite Forces With the tumor exposed, Dr. Soon-Shiong deploys the body’s natural killer (NK) cells and T-cells, supercharged by a breakthrough molecule called BioShield. This activates NK cells, stimulates killer T-cells, and—crucially—creates memory T-cells that remember the cancer’s signature. “For the first time, we’re seeing bladder cancer patients in complete remission for nine years, still alive, without losing their bladders,” he revealed. This isn’t just treatment; it’s a long-term defense system. Step 3: Orchestrate a Multi-Front Assault Cancer thrives by suppressing the immune system, but Dr. Soon-Shiong’s approach is a battlefield symphony. He educates T-cells with a tailored vaccine, activates killer macrophages, and suppresses the suppressors—all simultaneously. Radiation? Only in tiny, precise doses (SBRT) to expose, not destroy. “High-dose radiation kills your NK and T-cells,” he warns. This is precision warfare, not carpet bombing. A Future Without Suffering Unlike traditional cancer treatments that leave patients nauseous, bald, and broken, Dr. Soon-Shiong’s protocol is outpatient-based, minimizing suffering. “We’ve treated hundreds of patients this way,” he shared. Even more revolutionary? He envisions treating patients before surgery, using the tumor itself as a vaccine to train the immune system. Imagine a world where cancer is stopped in its tracks without invasive procedures. The American Red Cross of Cancer Dr. Soon-Shiong’s vision goes beyond individual patients. By extracting and cryopreserving NK and T-cells from a single pint of blood, his team can grow billions of these immune warriors, ready to be deployed for anyone. “We could become the American Red Cross of cancer,” he declared, hinting at a future where these innovations could even shape global health policy. Why This Matters Cancer isn’t just a disease; it’s a biological mastermind that demands respect and strategy. Dr. Soon-Shiong’s approach—expose, activate, educate, and suppress—offers hope to millions facing a life-threatening diagnosis. His work proves that with the right tools, we can turn the body into its own greatest weapon. The Call to Action The FDA must recognize this multi-pronged war requires battlefield awareness, not outdated single-drug approvals. Patients deserve access to these life-saving protocols now.

Camus

94,391 görüntüleme • 1 yıl önce